Novo Nordisk boss in US grilling over prices for weight-loss drugs
Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But CEO Lars Fruergaard Jørgensen has defended the company, attributing the elevated prices to "structural issues" within the US healthcare system.
Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But CEO Lars Fruergaard Jørgensen has defended the company, attributing the elevated prices to "structural issues" within the US healthcare system.
What's Your Reaction?
